Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Digital Health Funding Landscape Shifts as Clinical Workflow Startups Lead the Pack

Digital Health Funding Landscape Shifts as Clinical Workflow Startups Lead the Pack

Digital health funding has surged in the third quarter of 2025, with companies raising $3.5 billion across 107 deals, according to Rock Health's latest analysis. Year-to-date funding now stands at $9.9 billion, surpassing 2024's total through the third quarter. However, this apparent growth belies a more complex market landscape, characterized by the rise of unlabeled funding rounds and a shifting focus towards clinical workflow solutions.

NoahAI News10/7/2025
RSNA Ventures Partners with Rad AI to Integrate AI-Powered Radiology Solutions

RSNA Ventures Partners with Rad AI to Integrate AI-Powered Radiology Solutions

The Radiological Society of North America (RSNA) has launched a new venture arm, RSNA Ventures, and announced a strategic partnership with Rad AI to revolutionize radiologists' workflow through the integration of generative AI technology. This collaboration aims to address the growing challenges faced by radiologists, including increasing case volumes, workforce shortages, and the need for rapid access to trusted, peer-reviewed information.

NoahAI News10/7/2025
AstraZeneca Expands AI Partnerships with $555M Algen Alliance, Bolstering Immunology Pipeline

AstraZeneca Expands AI Partnerships with $555M Algen Alliance, Bolstering Immunology Pipeline

AstraZeneca continues to strengthen its artificial intelligence (AI) capabilities through strategic partnerships, with its latest collaboration targeting novel therapies in immunology. The pharmaceutical giant announced a deal worth up to $555 million with California-based Algen Biotechnologies, marking another significant investment in AI-driven drug discovery.

NoahAI News10/6/2025
Chiesi and Arbor Biotechnologies Forge $2.1B Alliance for Rare Disease Gene Editing Therapies

Chiesi and Arbor Biotechnologies Forge $2.1B Alliance for Rare Disease Gene Editing Therapies

Italian pharmaceutical company Chiesi Group has entered into a landmark collaboration with Arbor Biotechnologies, a U.S.-based gene editing startup, in a deal potentially worth over $2.1 billion. The partnership, announced on October 6, 2025, centers around the development of innovative gene editing treatments for rare diseases, with a primary focus on primary hyperoxaluria type 1 (PH1).

NoahAI News10/6/2025
Myeloid Therapeutics Rebrands as Create Medicines, Expands Focus Beyond Myeloid Cells

Myeloid Therapeutics Rebrands as Create Medicines, Expands Focus Beyond Myeloid Cells

Myeloid Therapeutics, a biotech company founded in 2021, has undergone a significant transformation, rebranding itself as Create Medicines to reflect its expanded pipeline and research focus. The company, which initially centered on myeloid cell-based therapies, has broadened its scope to include T cells and NK cells, marking a strategic shift in its approach to immunotherapy.

NoahAI News10/6/2025
Skye Bioscience's CB1 Blocker Fails to Reduce Weight in Phase 2 Obesity Study

Skye Bioscience's CB1 Blocker Fails to Reduce Weight in Phase 2 Obesity Study

Skye Bioscience's obesity candidate, nimacimab, has failed to demonstrate significant weight reduction in a phase 2 clinical trial, dealing another blow to the CB1 inhibitor class of drugs. The study results, released on October 6, 2025, have sent the company's shares plummeting by over 60% in early premarket trading.

NoahAI News10/6/2025
AstraZeneca and Algen Biotechnologies Forge $555M AI Partnership for Immunology Drug Discovery

AstraZeneca and Algen Biotechnologies Forge $555M AI Partnership for Immunology Drug Discovery

AstraZeneca, the British-Swedish pharmaceutical giant, has entered into a significant collaboration with San Francisco-based Algen Biotechnologies, marking another major step in the integration of artificial intelligence (AI) into drug discovery. The partnership, valued at up to $555 million, aims to accelerate the identification of novel immunology targets using Algen's advanced AI platform.

NoahAI News10/6/2025
T Cell Engagers: A Promising Approach to Revolutionize Autoimmune Disease Treatment

T Cell Engagers: A Promising Approach to Revolutionize Autoimmune Disease Treatment

In a significant development for the pharmaceutical industry, T cell engagers are emerging as a potential game-changer in the treatment of autoimmune diseases. This novel approach aims to redefine autoimmune care by focusing on achieving lasting remission and improving patient experience, moving away from traditional symptom management strategies.

NoahAI News10/6/2025
Patient Recruitment Partners: Strategic Allies for Successful Clinical Trials

Patient Recruitment Partners: Strategic Allies for Successful Clinical Trials

In the ever-evolving landscape of clinical trials, pharmaceutical companies are increasingly recognizing the value of engaging patient recruitment partners early in the study process. This shift in approach is transforming these specialists from last-minute rescuers to integral strategic allies, potentially saving sponsors millions in costs and months in delays.

NoahAI News10/6/2025
Mixed Signals in Cell and Gene Therapy as Industry Gathers for Meeting on the Mesa

Mixed Signals in Cell and Gene Therapy as Industry Gathers for Meeting on the Mesa

The cell and gene therapy (CGT) sector finds itself at a crossroads as industry leaders convene for the annual Meeting on the Mesa in Phoenix, Arizona. Recent months have seen a flurry of high-profile acquisitions juxtaposed against ongoing commercialization challenges, painting a complex picture for investors and stakeholders alike.

NoahAI News10/6/2025
Beyond BTK Inhibitors: The Next Frontier in Multiple Sclerosis Treatment

Beyond BTK Inhibitors: The Next Frontier in Multiple Sclerosis Treatment

Multiple sclerosis (MS) researchers and pharmaceutical companies are pushing the boundaries of treatment options, with a focus on neuroprotection and remyelination that could potentially transcend traditional symptom management. While Bruton's tyrosine kinase (BTK) inhibitors are poised to make a significant impact, emerging therapies are exploring novel mechanisms to halt or even reverse disease progression.

NoahAI News10/6/2025
Gene Therapy's Safety Challenges Reshape Industry Economics and Development Strategies

Gene Therapy's Safety Challenges Reshape Industry Economics and Development Strategies

In a rapidly evolving landscape, the gene therapy sector faces a critical juncture as safety concerns and economic realities collide, forcing companies to reevaluate their approaches to drug development and delivery. Recent setbacks have highlighted the need for innovative strategies to ensure both patient safety and commercial viability, with targeted delivery and human-relevant testing emerging as key focus areas.

NoahAI News10/6/2025
«1...525354...67»